Date: 2015-10-21
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Pfizer (USA - NY)
Product: avelumab in combination with crizotinib or lorlatinib (PF-06463922)
Action
mechanism: monoclonal antibody/immune checkpoint inhibitor/tyrosine kinase inhibitor/kinase inhibitor/multi-kinase inhibitor. Xalkori® (crizotinib)'s antineoplastic activity is linked to the selective inhibition of the ALK receptor tyrosine kinase (RTK) and its oncogenic variants (i.e. ALK fusion events and selected ALK mutations). Xalkori® is also an inhibitor of the Hepatocyte Growth Factor Receptor (HGFR, c-Met) RTK. Lorlatinib (PF-06463922) is an Alk/ros1 tyrosine kinase inhibitor. MSB0010718C (avelumab) is a fully human IgG1 monoclonal antibody that binds to the PD-L1 (programmed death-ligand 1) protein, which is present at high levels in many cancer types. By competitively blocking the interaction with PD-1 receptors, it is believed that MSB0010718C thereby restores anti-tumor T-cell responses and inhibits tumor growth. Pfizer and Merck KGaA are jointly developing avelumab (MSB0010718C), an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.
Disease: non-small cell lung cancer (NSCLC)
Therapeutic area: Cancer - Oncology
Country: Australia, Japan, Republic of Korea, Spain, USA
Trial
details: The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922. (NCT02584634)
Latest
news: * On October 21, 2015, a Phase 2 trial sponsored by Pfizer was published on the NIH website ClinicalTrials.gov for avelumab in combination with crizotinib or lorlatinib and is currently recruiting participants.
